Nunzia Pharmaceutical Company EBIT

The latest EBIT for NUNZ is $-97M as of September 2022. That compares with $-58K in the prior-year period — down 167357.7% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Nunzia Pharmaceutical Company's historical trend and sector peers before judging valuation or financial health.

Over the past year, NUNZ's EBIT moved from $-58K to $-97M — a 167357.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nunzia Pharmaceutical Company's operating scale or balance-sheet position.

Against its sector companies, NUNZ currently prints $-97M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Nunzia Pharmaceutical Company's growth, margins, and balance sheet.

A EBIT figure of $-97M for NUNZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting NUNZ's EBIT ($-97M), review year-over-year change from $-58K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.